Should losartan be administered following brain injury? (Q38262865)

1 September 2017

1 reference

title

Should losartan be administered following brain injury? (English)

1 reference

1 September 2017

1 reference

5

Uwe Heinemann

1 reference

1 September 2017

0 references

Alon Friedman

1

1 reference

1 September 2017

Guy Bar-Klein

2

1 reference

1 September 2017

Yonatan Serlin

3

1 reference

1 September 2017

Yisrael Parmet

4

1 reference

1 September 2017

Daniela Kaufer

6

1 reference

1 September 2017

27 October 2014

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

1 September 2017

1 reference

1 September 2017

14

1 reference

1 September 2017

1365-1375

1 reference

1 September 2017

12

1 reference

Factors affecting cognitive outcome in early pediatric stroke.

1 September 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Blood-brain barrier breakdown-inducing astrocytic transformation: novel targets for the prevention of epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Overview and introduction: the blood-brain barrier in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Structure and function of the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Astrocyte-endothelial interactions at the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Mechanisms of disease: the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

The blood-brain barrier and epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Frequent blood-brain barrier disruption in the human cerebral cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Seizure-promoting effect of blood-brain barrier disruption

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Blood-brain barrier disruption results in delayed functional and structural alterations in the rat neocortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

TGF-beta receptor-mediated albumin uptake into astrocytes is involved in neocortical epileptogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Lasting blood-brain barrier disruption induces epileptic focus in the rat somatosensory cortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Transcriptome profiling reveals TGF-beta signaling involvement in epileptogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Losartan prevents acquired epilepsy via TGF-β signaling suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Astrocytic dysfunction in epileptogenesis: consequence of altered potassium and glutamate homeostasis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Peri-infarct blood-brain barrier dysfunction facilitates induction of spreading depolarization associated with epileptiform discharges.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Long-lasting pro-ictogenic effects induced in vivo by rat brain exposure to serum albumin in the absence of concomitant pathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

The epidemiology and impact of traumatic brain injury: a brief overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Blood-brain barrier breakdown as a therapeutic target in traumatic brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Trends in head injury outcome from 1989 to 2003 and the effect of neurosurgical care: an observational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

High-volume trauma centers have better outcomes treating traumatic brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Importance of preclinical research in the development of neuroprotective strategies for ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

A review of neuroprotection pharmacology and therapies in patients with acute traumatic brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

21 January 2018

Traumatic brain injury

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Prognosis and clinical trial design in traumatic brain injury: the IMPACT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Clinical trials in head injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Early management of severe traumatic brain injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Early indicators of prognosis in 846 cases of severe traumatic brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

The blood-brain barrier in health and chronic neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Long-term cognitive outcome in moderate to severe traumatic brain injury: a meta-analysis examining timed and untimed tests at 1 and 4.5 or more years after injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

A population-based study of seizures after traumatic brain injuries

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Blood-brain barrier dysfunction, TGFβ signaling, and astrocyte dysfunction in epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Neutralization of transforming growth factor-beta attenuates hypertension and prevents renal injury in uremic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Functional evidence that the angiotensin antagonist losartan crosses the blood-brain barrier in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Central nervous system blockade by peripheral administration of AT1 receptor blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Evaluation of the ability of irbesartan to cross the blood-brain barrier following acute intragastric treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Risk Factors for Posttraumatic Seizures in Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Epidemiology of Posttraumatic Epilepsy: A Critical Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Early seizures after mild closed head injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Long-term risk of epilepsy after traumatic brain injury in children and young adults: a population-based cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Analyzing risk factors for late posttraumatic seizures: a prospective, multicenter investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

A population-based study of risk of epilepsy after hospitalization for traumatic brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Correlates of posttraumatic epilepsy 35 years following combat brain injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Risk of epilepsy after traumatic brain injury: a retrospective population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Visualising microglial activation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Imaging inflammation in a patient with epilepsy due to focal cortical dysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Mood, cognition and in vivo protein imaging: the emerging nexus in clinical neuroscience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

In Vivo Detection of Diffuse Inflammation in Secondary Progressive Multiple Sclerosis Using PET Imaging and the Radioligand ¹¹C-PK11195.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Non-invasive detection of hippocampal sclerosis: correlation between metabolite alterations detected by (1)H-MRS and neuropathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Medial temporal atrophy and memory impairment in early stage of Alzheimer's disease: an MRI volumetric and memory assessment study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Blood-brain barrier breakdown following traumatic brain injury: a possible role in posttraumatic epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Quantitative imaging assessment of blood-brain barrier permeability in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Inflammation in epilepsy: clinical observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Astrocytic transforming growth factor-beta signaling reduces subacute neuroinflammation after stroke in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Protective effect of transforming growth factor beta 1 on experimental autoimmune diseases in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Transforming growth factor-beta 1 prevents glutamate neurotoxicity in rat neocortical cultures and protects mouse neocortex from ischemic injury in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Inhibition of glial scarring in the injured rat brain by a recombinant human monoclonal antibody to transforming growth factor-beta2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

TGF-β promotes glioma cell growth via activating Nodal expression through Smad and ERK1/2 pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Smad3 deficiency increases cortical and hippocampal neuronal loss following traumatic brain injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Smad3 null mice display more rapid wound closure and reduced scar formation after a stab wound to the cerebral cortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Decorin prevents the development of juvenile communicating hydrocephalus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Inhibition of transforming growth factor-β attenuates brain injury and neurological deficits in a rat model of germinal matrix hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Use of an adult rat retinal explant model for screening of potential retinal ganglion cell neuroprotective therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Telmisartan ameliorates glutamate-induced neurotoxicity: roles of AT(1) receptor blockade and PPARγ activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Angiotensin II type 1 receptor blocker losartan prevents and rescues cerebrovascular, neuropathological and cognitive deficits in an Alzheimer's disease model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Autonomic, locomotor and cardiac abnormalities in a mouse model of muscular dystrophy: targeting the renin-angiotensin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Angiotensin type 1 receptor inhibition enhances the extinction of fear memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Peroxisome proliferator-activated receptor-γ activation with angiotensin II type 1 receptor blockade is pivotal for the prevention of blood-brain barrier impairment and cognitive decline in type 2 diabetic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Neuronal activation in the central nervous system of rats in the initial stage of chronic kidney disease-modulatory effects of losartan and moxonidine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

The neuroprotective effect of losartan through inhibiting AT1/ASK1/MKK4/JNK3 pathway following cerebral I/R in rat hippocampal CA1 region.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Role of angiotensin II in the brain inflammatory events during experimental diabetes in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Central angiotensin II stimulation promotes β amyloid production in Sprague Dawley rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

The effects of poststroke captopril and losartan treatment on cerebral blood flow autoregulation in SHRsp with hemorrhagic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Pathophysiology of target-organ disease: does angiotensin II remain the key?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

Effects of candesartan on cardiovascular outcomes in Japanese hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.972945

10.1586/14737175.2014.972945

21 January 2018

Identifiers

DOI

1 reference

1 September 2017

1 reference